- Home
- TRMD vs DAWN Comparison
TRMD vs DAWN Comparison
Compare TRMD & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- DAWN
- Stock Information
- Founded
- TRMD 1889
- DAWN 2018
- Country
- TRMD United Kingdom
- DAWN United States
- Employees
- TRMD N/A
- DAWN 174
- Industry
- TRMD Marine Transportation
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- DAWN Health Care
- Exchange
- TRMD Nasdaq
- DAWN Nasdaq
- Market Cap
- TRMD 1.9B
- DAWN 1.3B
- IPO Year
- TRMD N/A
- DAWN 2021
- Fundamental
- Price
- TRMD $18.29
- DAWN $12.64
- Analyst Decision
- TRMD Buy
- DAWN Strong Buy
- Analyst Count
- TRMD 1
- DAWN 7
- Target Price
- TRMD $48.00
- DAWN $36.17
- AVG Volume (30 Days)
- TRMD 1.3M
- DAWN 898.1K
- Earning Date
- TRMD 11-07-2024
- DAWN 10-30-2024
- Dividend Yield
- TRMD 26.39%
- DAWN N/A
- EPS Growth
- TRMD N/A
- DAWN N/A
- EPS
- TRMD 7.70
- DAWN N/A
- Revenue
- TRMD $1,641,593,000.00
- DAWN $101,953,000.00
- Revenue This Year
- TRMD N/A
- DAWN N/A
- Revenue Next Year
- TRMD N/A
- DAWN $36.10
- P/E Ratio
- TRMD $2.54
- DAWN N/A
- Revenue Growth
- TRMD 3.90
- DAWN N/A
- 52 Week Low
- TRMD $18.01
- DAWN $11.94
- 52 Week High
- TRMD $40.47
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- TRMD 24.01
- DAWN 34.93
- Support Level
- TRMD $18.72
- DAWN $12.42
- Resistance Level
- TRMD $19.48
- DAWN $12.95
- Average True Range (ATR)
- TRMD 0.56
- DAWN 0.48
- MACD
- TRMD 0.06
- DAWN -0.08
- Stochastic Oscillator
- TRMD 8.28
- DAWN 10.78
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.